These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29774943)

  • 1. [Progress in prophylatic hyperthermic intraperitoneal chemotherapy for advanced gastric carcinoma].
    Chen X; Luo J; Liu H; Chen Y; Hu Y; Li T; Lin T; Zhu Y; Zhao M; Chen H; Li G; Yu J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 May; 21(5):593-599. PubMed ID: 29774943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of surgery combined with hyperthermic intraperitoneal chemotherapy in the treatment of advanced gastric cancer: a meta-analysis].
    Ni Z; Li C; Yan C; Liu W; Yao X; Chen M; Yan M; Zhu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Dec; 19(12):1406-1413. PubMed ID: 28000200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
    Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
    BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hyperthermic intraperitoneal chemotherapy on survival and recurrence rates in advanced gastric cancer: a systematic review and meta-analysis.
    Patel M; Arora A; Mukherjee D; Mukherjee S
    Int J Surg; 2023 Aug; 109(8):2435-2450. PubMed ID: 37158149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study.
    Beeharry MK; Zhu ZL; Liu WT; Yao XX; Yan M; Zhu ZG
    BMC Cancer; 2019 Sep; 19(1):932. PubMed ID: 31533660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Analysis of Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: a Propensity Score-Matched Analysis.
    Liu L; Zheng L; Liu S; Zhang M; Zhang S; Jiang Z; Qin C; Wang D
    J Gastrointest Surg; 2023 Nov; 27(11):2297-2307. PubMed ID: 37715013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center.
    Rosa F; Galiandro F; Ricci R; Di Miceli D; Longo F; Quero G; Tortorelli AP; Alfieri S
    Langenbecks Arch Surg; 2021 Jun; 406(4):1071-1080. PubMed ID: 33611693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages.
    Zhang JF; Lv L; Zhao S; Zhou Q; Jiang CG
    Ann Surg Oncol; 2022 May; 29(5):3170-3186. PubMed ID: 35175455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer.
    Desiderio J; Chao J; Melstrom L; Warner S; Tozzi F; Fong Y; Parisi A; Woo Y
    Eur J Cancer; 2017 Jul; 79():1-14. PubMed ID: 28456089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study.
    Yu P; Huang X; Huang L; Dai G; Xu Q; Fang J; Ye Z; Chai T; Du Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11491-11498. PubMed ID: 37392201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center.
    Rosa F; Galiandro F; Ricci R; Di Miceli D; Longo F; Quero G; Tortorelli AP; Alfieri S
    Langenbecks Arch Surg; 2021 Sep; 406(6):1847-1857. PubMed ID: 33704561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
    Canbay E; Mizumoto A; Ichinose M; Ishibashi H; Sako S; Hirano M; Takao N; Yonemura Y
    Ann Surg Oncol; 2014 Apr; 21(4):1147-52. PubMed ID: 24356799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of prophylactic hyperthermic intraperitoneal chemotherapy in the management of serosal involved gastric cancer.
    Saladino E; Fleres F; Mazzeo C; Pruiti V; Scollica M; Rossitto M; Cucinotta E; Macrì A
    Anticancer Res; 2014 Apr; 34(4):2019-22. PubMed ID: 24692741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary results of prophylactic HIPEC in patients with locally advanced gastric cancer.
    Graziosi L; Cantarella F; Mingrone E; Gunnellini M; Cavazzoni E; Liberati M; Donini A
    Ann Ital Chir; 2013; 84(5):551-6. PubMed ID: 24140896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial.
    Klaver CE; Musters GD; Bemelman WA; Punt CJ; Verwaal VJ; Dijkgraaf MG; Aalbers AG; van der Bilt JD; Boerma D; Bremers AJ; Burger JW; Buskens CJ; Evers P; van Ginkel RJ; van Grevenstein WM; Hemmer PH; de Hingh IH; Lammers LA; van Leeuwen BL; Meijerink WJ; Nienhuijs SW; Pon J; Radema SA; van Ramshorst B; Snaebjornsson P; Tuynman JB; Te Velde EA; Wiezer MJ; de Wilt JH; Tanis PJ
    BMC Cancer; 2015 May; 15():428. PubMed ID: 26003804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis.
    Detroz B; Laurent S; Honoré P; Blaffart F; Limet R; Meurisse M
    Acta Chir Belg; 2004 Aug; 104(4):377-83. PubMed ID: 15469146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination from Small Bowel Malignancy: Results from a Single Specialized Center.
    Liu Y; Ishibashi H; Takeshita K; Mizumoto A; Hirano M; Sako S; Takegawa S; Takao N; Ichinose M; Yonemura Y
    Ann Surg Oncol; 2016 May; 23(5):1625-31. PubMed ID: 26717938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic hyperthermic intraperitoneal chemotherapy for patients with clinical T4 gastric cancer.
    Lee TY; Hsu CH; Fan HL; Liao GS; Chen TW; Chan DC
    Eur J Surg Oncol; 2022 Sep; 48(9):1972-1979. PubMed ID: 35508455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Braam HJ; van Oudheusden TR; de Hingh IH; Nienhuijs SW; Boerma D; Wiezer MJ; van Ramshorst B
    J Surg Oncol; 2014 Jun; 109(8):841-7. PubMed ID: 24619813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.